{"product_id":"entresto","title":"Entresto","description":"\u003ch3 data-start=\"368\" data-end=\"403\"\u003eWhat is Sacubitril\/Valsartan?\u003c\/h3\u003e\r\n\u003cp data-start=\"404\" data-end=\"587\"\u003eSacubitril\/Valsartan is a combination medication used primarily for the treatment of chronic heart failure with reduced ejection fraction (HFrEF). It contains two active components:\u003c\/p\u003e\r\n\u003cul data-start=\"588\" data-end=\"736\"\u003e\r\n\u003cli data-start=\"588\" data-end=\"678\"\u003e\n\u003cstrong data-start=\"590\" data-end=\"604\"\u003eSacubitril\u003c\/strong\u003e, a prodrug that is converted to an active neprilysin inhibitor (LBQ657)\u003c\/li\u003e\r\n\u003cli data-start=\"679\" data-end=\"736\"\u003e\n\u003cstrong data-start=\"681\" data-end=\"694\"\u003eValsartan\u003c\/strong\u003e, an angiotensin II receptor blocker (ARB)\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"738\" data-end=\"830\"\u003eThis unique combination is known as an \u003cstrong data-start=\"777\" data-end=\"829\"\u003eAngiotensin Receptor-Neprilysin Inhibitor (ARNI)\u003c\/strong\u003e.\u003c\/p\u003e\r\n\u003cp data-start=\"832\" data-end=\"926\"\u003e\u003cem data-start=\"832\" data-end=\"926\"\u003eReference: \u003ca target=\"_new\" rel=\"noopener\" data-start=\"844\" data-end=\"925\"\u003eMcMurray et al., NEJM 2014\u003c\/a\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"928\" data-end=\"931\"\u003e\r\n\u003ch3 data-start=\"933\" data-end=\"997\"\u003eWhat are the other popular names for Sacubitril\/Valsartan?\u003c\/h3\u003e\r\n\u003cp data-start=\"998\" data-end=\"1174\"\u003eSacubitril\/Valsartan is most commonly marketed under the brand name \u003cstrong data-start=\"1066\" data-end=\"1078\"\u003eEntresto\u003c\/strong\u003e. In clinical literature, it is also referred to by its generic components—sacubitril\/valsartan.\u003c\/p\u003e\r\n\u003cp data-start=\"1176\" data-end=\"1248\"\u003e\u003cem data-start=\"1176\" data-end=\"1248\"\u003eReference: \u003ca target=\"_new\" rel=\"noopener\" data-start=\"1188\" data-end=\"1247\"\u003eDrugs.com – Entresto\u003c\/a\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"1250\" data-end=\"1253\"\u003e\r\n\u003ch3 data-start=\"1255\" data-end=\"1317\"\u003eWhat is the drug classification of Sacubitril\/Valsartan?\u003c\/h3\u003e\r\n\u003cp data-start=\"1318\" data-end=\"1625\"\u003eSacubitril\/Valsartan is classified as an \u003cstrong data-start=\"1359\" data-end=\"1411\"\u003eAngiotensin Receptor-Neprilysin Inhibitor (ARNI)\u003c\/strong\u003e. It falls under the broader category of \u003cstrong data-start=\"1452\" data-end=\"1502\"\u003edisease‑modifying antirheumatic drugs (DMARDs)\u003c\/strong\u003e in heart failure management, specifically aimed at reducing cardiovascular morbidity and mortality in patients with HFrEF.\u003c\/p\u003e\r\n\u003cp data-start=\"1627\" data-end=\"1705\"\u003e\u003cem data-start=\"1627\" data-end=\"1705\"\u003eReference: \u003ca href=\"https:\/\/www.acc.org\/\" target=\"_new\" rel=\"noopener\" data-start=\"1639\" data-end=\"1704\"\u003eAmerican College of Cardiology Guidelines\u003c\/a\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"1707\" data-end=\"1710\"\u003e\r\n\u003ch3 data-start=\"1712\" data-end=\"1769\"\u003eWhat is the mode of action of Sacubitril\/Valsartan?\u003c\/h3\u003e\r\n\u003cp data-start=\"1770\" data-end=\"1848\"\u003eSacubitril\/Valsartan exerts its therapeutic effect through a dual mechanism:\u003c\/p\u003e\r\n\u003cul data-start=\"1849\" data-end=\"2433\"\u003e\r\n\u003cli data-start=\"1849\" data-end=\"2216\"\u003e\n\u003cstrong data-start=\"1851\" data-end=\"1900\"\u003eNeprilysin Inhibition (Sacubitril Component):\u003c\/strong\u003e Sacubitril is converted to LBQ657, which inhibits neprilysin. Neprilysin is an enzyme responsible for degrading natriuretic peptides, bradykinin, and other vasoactive substances. Inhibition increases the levels of these peptides, promoting vasodilation, natriuresis, and diuresis, and reducing cardiac remodeling.\u003c\/li\u003e\r\n\u003cli data-start=\"2217\" data-end=\"2433\"\u003e\n\u003cstrong data-start=\"2219\" data-end=\"2278\"\u003eAngiotensin II Receptor Blockade (Valsartan Component):\u003c\/strong\u003e Valsartan selectively blocks the angiotensin II type‑1 (AT1) receptor, thereby reducing vasoconstriction, aldosterone secretion, and adverse remodeling.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"2435\" data-end=\"2552\"\u003eTogether, these actions lower blood pressure, decrease cardiac workload, and improve overall cardiovascular outcomes.\u003c\/p\u003e\r\n\u003cp data-start=\"2554\" data-end=\"2747\"\u003e\u003cem data-start=\"2554\" data-end=\"2747\"\u003eReference: \u003ca target=\"_new\" rel=\"noopener\" data-start=\"2566\" data-end=\"2647\"\u003eMcMurray et al., NEJM 2014\u003c\/a\u003e, \u003ca target=\"_new\" rel=\"noopener\" data-start=\"2649\" data-end=\"2746\"\u003eFDA Entresto Label\u003c\/a\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"2749\" data-end=\"2752\"\u003e\r\n\u003ch3 data-start=\"2754\" data-end=\"2793\"\u003eHow is Sacubitril\/Valsartan used?\u003c\/h3\u003e\r\n\u003cp data-start=\"2794\" data-end=\"2834\"\u003eSacubitril\/Valsartan is indicated for:\u003c\/p\u003e\r\n\u003cul data-start=\"2835\" data-end=\"3228\"\u003e\r\n\u003cli data-start=\"2835\" data-end=\"3022\"\u003e\n\u003cstrong data-start=\"2837\" data-end=\"2855\"\u003eChronic HFrEF:\u003c\/strong\u003e It is used in adult patients with symptomatic chronic heart failure (NYHA class II–IV) to reduce the risk of cardiovascular death and heart failure hospitalization.\u003c\/li\u003e\r\n\u003cli data-start=\"3023\" data-end=\"3228\"\u003eIt is recommended as an adjunct to standard heart failure therapy and is typically used in patients who have been stabilized on ACE inhibitors or ARBs (with an appropriate washout period when switching).\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"3230\" data-end=\"3358\"\u003e\u003cem data-start=\"3230\" data-end=\"3358\"\u003eReference: \u003ca target=\"_new\" rel=\"noopener\" data-start=\"3242\" data-end=\"3357\"\u003eFDA Entresto Prescribing Information\u003c\/a\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"3360\" data-end=\"3363\"\u003e\r\n\u003ch3 data-start=\"3365\" data-end=\"3446\"\u003eWhat is the recommended dosage and administration for Sacubitril\/Valsartan?\u003c\/h3\u003e\r\n\u003cul data-start=\"3447\" data-end=\"3888\"\u003e\r\n\u003cli data-start=\"3447\" data-end=\"3565\"\u003e\n\u003cstrong data-start=\"3449\" data-end=\"3467\"\u003eStarting Dose:\u003c\/strong\u003e Patients not previously on an ACE inhibitor or ARB typically start at \u003cstrong data-start=\"3538\" data-end=\"3562\"\u003e49\/51 mg twice daily\u003c\/strong\u003e.\u003c\/li\u003e\r\n\u003cli data-start=\"3566\" data-end=\"3697\"\u003e\n\u003cstrong data-start=\"3568\" data-end=\"3582\"\u003eTitration:\u003c\/strong\u003e The dose is usually increased to \u003cstrong data-start=\"3616\" data-end=\"3641\"\u003e97\/103 mg twice daily\u003c\/strong\u003e as tolerated to achieve optimal therapeutic benefits.\u003c\/li\u003e\r\n\u003cli data-start=\"3698\" data-end=\"3888\"\u003e\n\u003cstrong data-start=\"3700\" data-end=\"3719\"\u003eAdministration:\u003c\/strong\u003e The medication is taken orally, with or without food. If transitioning from an ACE inhibitor, a washout period of 36 hours is required to reduce the risk of angioedema.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"3890\" data-end=\"4000\"\u003e\u003cem data-start=\"3890\" data-end=\"4000\"\u003eReference: \u003ca target=\"_new\" rel=\"noopener\" data-start=\"3902\" data-end=\"3999\"\u003eFDA Entresto Label\u003c\/a\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"4002\" data-end=\"4005\"\u003e\r\n\u003ch3 data-start=\"4007\" data-end=\"4080\"\u003eWhat prescribing information is important for Sacubitril\/Valsartan?\u003c\/h3\u003e\r\n\u003cul data-start=\"4081\" data-end=\"4670\"\u003e\r\n\u003cli data-start=\"4081\" data-end=\"4239\"\u003e\n\u003cstrong data-start=\"4083\" data-end=\"4099\"\u003eIndications:\u003c\/strong\u003e Sacubitril\/Valsartan is indicated for reducing the risk of cardiovascular death and heart failure hospitalization in patients with HFrEF.\u003c\/li\u003e\r\n\u003cli data-start=\"4240\" data-end=\"4420\"\u003e\n\u003cstrong data-start=\"4242\" data-end=\"4264\"\u003eContraindications:\u003c\/strong\u003e It is contraindicated in patients with a history of angioedema related to ACE inhibitor or ARB therapy, and those with concomitant use of ACE inhibitors.\u003c\/li\u003e\r\n\u003cli data-start=\"4421\" data-end=\"4549\"\u003e\n\u003cstrong data-start=\"4423\" data-end=\"4445\"\u003ePatient Selection:\u003c\/strong\u003e It is essential to assess renal function, electrolytes, and blood pressure before and during therapy.\u003c\/li\u003e\r\n\u003cli data-start=\"4550\" data-end=\"4670\"\u003e\n\u003cstrong data-start=\"4552\" data-end=\"4567\"\u003eMonitoring:\u003c\/strong\u003e Regular monitoring of kidney function, serum potassium, liver enzymes, and blood pressure is required.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"4672\" data-end=\"4748\"\u003e\u003cem data-start=\"4672\" data-end=\"4748\"\u003eReference: \u003ca href=\"https:\/\/www.heart.org\/\" target=\"_new\" rel=\"noopener\" data-start=\"4684\" data-end=\"4747\"\u003eAmerican Heart Association Guidelines\u003c\/a\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"4750\" data-end=\"4753\"\u003e\r\n\u003ch3 data-start=\"4755\" data-end=\"4842\"\u003eWhat are the safety information, warnings, and cautions for Sacubitril\/Valsartan?\u003c\/h3\u003e\r\n\u003cul data-start=\"4843\" data-end=\"5741\"\u003e\r\n\u003cli data-start=\"4843\" data-end=\"4974\"\u003e\n\u003cstrong data-start=\"4845\" data-end=\"4868\"\u003eSafety Information:\u003c\/strong\u003e\r\n\u003cul data-start=\"4873\" data-end=\"4974\"\u003e\r\n\u003cli data-start=\"4873\" data-end=\"4974\"\u003eCommon adverse reactions include hypotension, hyperkalemia, renal impairment, cough, and dizziness.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"4975\" data-end=\"5741\"\u003e\n\u003cstrong data-start=\"4977\" data-end=\"5001\"\u003eWarnings \u0026amp; Cautions:\u003c\/strong\u003e\r\n\u003cul data-start=\"5006\" data-end=\"5741\"\u003e\r\n\u003cli data-start=\"5006\" data-end=\"5147\"\u003e\n\u003cstrong data-start=\"5008\" data-end=\"5028\"\u003eAngioedema Risk:\u003c\/strong\u003e There is an increased risk of angioedema, particularly in patients with a history of angioedema from ACE inhibitors.\u003c\/li\u003e\r\n\u003cli data-start=\"5150\" data-end=\"5235\"\u003e\n\u003cstrong data-start=\"5152\" data-end=\"5168\"\u003eHypotension:\u003c\/strong\u003e Caution is advised in patients with low baseline blood pressure.\u003c\/li\u003e\r\n\u003cli data-start=\"5238\" data-end=\"5372\"\u003e\n\u003cstrong data-start=\"5240\" data-end=\"5259\"\u003eRenal Function:\u003c\/strong\u003e Monitor renal function as deterioration may occur, particularly in patients with preexisting renal impairment.\u003c\/li\u003e\r\n\u003cli data-start=\"5375\" data-end=\"5465\"\u003e\n\u003cstrong data-start=\"5377\" data-end=\"5394\"\u003eHyperkalemia:\u003c\/strong\u003e Elevated potassium levels can occur; periodic monitoring is essential.\u003c\/li\u003e\r\n\u003cli data-start=\"5468\" data-end=\"5741\"\u003e\n\u003cstrong data-start=\"5470\" data-end=\"5492\"\u003eDrug Interactions:\u003c\/strong\u003e\r\n\u003cul data-start=\"5499\" data-end=\"5741\"\u003e\r\n\u003cli data-start=\"5499\" data-end=\"5558\"\u003e\n\u003cstrong data-start=\"5501\" data-end=\"5520\"\u003eACE Inhibitors:\u003c\/strong\u003e Concomitant use is contraindicated.\u003c\/li\u003e\r\n\u003cli data-start=\"5563\" data-end=\"5654\"\u003e\n\u003cstrong data-start=\"5565\" data-end=\"5613\"\u003ePotassium-Sparing Diuretics and Supplements:\u003c\/strong\u003e May increase the risk of hyperkalemia.\u003c\/li\u003e\r\n\u003cli data-start=\"5659\" data-end=\"5738\"\u003e\n\u003cstrong data-start=\"5661\" data-end=\"5672\"\u003eNSAIDs:\u003c\/strong\u003e May impair renal function and reduce the antihypertensive effect.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"5742\" data-end=\"5948\"\u003e\u003cem data-start=\"5742\" data-end=\"5948\"\u003eReference: \u003ca target=\"_new\" rel=\"noopener\" data-start=\"5754\" data-end=\"5864\"\u003eFDA Entresto Safety Information\u003c\/a\u003e, \u003ca target=\"_new\" rel=\"noopener\" data-start=\"5866\" data-end=\"5947\"\u003eMcMurray et al., NEJM 2014\u003c\/a\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"5950\" data-end=\"5953\"\u003e\r\n\u003ch3 data-start=\"5955\" data-end=\"6042\"\u003eWhat additional drug interactions should be considered with Sacubitril\/Valsartan?\u003c\/h3\u003e\r\n\u003cul data-start=\"6043\" data-end=\"6540\"\u003e\r\n\u003cli data-start=\"6043\" data-end=\"6240\"\u003e\n\u003cstrong data-start=\"6045\" data-end=\"6076\"\u003eCYP450 Enzyme Interactions:\u003c\/strong\u003e Although Sacubitril\/Valsartan is not primarily metabolized by CYP enzymes, caution is warranted with medications that may alter blood pressure or renal function.\u003c\/li\u003e\r\n\u003cli data-start=\"6241\" data-end=\"6416\"\u003e\n\u003cstrong data-start=\"6243\" data-end=\"6271\"\u003eOther Antihypertensives:\u003c\/strong\u003e Concomitant use with other blood pressure–lowering agents (such as calcium channel blockers or beta-blockers) may enhance hypotensive effects.\u003c\/li\u003e\r\n\u003cli data-start=\"6417\" data-end=\"6540\"\u003e\n\u003cstrong data-start=\"6419\" data-end=\"6433\"\u003eDiuretics:\u003c\/strong\u003e Use with loop or thiazide diuretics requires monitoring for electrolyte disturbances and volume depletion.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"6542\" data-end=\"6675\"\u003e\u003cem data-start=\"6542\" data-end=\"6675\"\u003eReference: \u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/\" target=\"_new\" rel=\"noopener\" data-start=\"6554\" data-end=\"6619\"\u003eClinical Pharmacology Reviews\u003c\/a\u003e, \u003ca href=\"https:\/\/www.rheumatology.org\/\" target=\"_new\" rel=\"noopener\" data-start=\"6621\" data-end=\"6674\"\u003eACR Guidelines, 2023\u003c\/a\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"6677\" data-end=\"6680\"\u003e\r\n\u003ch3 data-start=\"6682\" data-end=\"6764\"\u003eWhere can I learn more about Sacubitril\/Valsartan and its clinical evidence?\u003c\/h3\u003e\r\n\u003cp data-start=\"6765\" data-end=\"6901\"\u003eFor further details on clinical studies, dosing guidelines, and safety monitoring, healthcare professionals and patients can refer to:\u003c\/p\u003e\r\n\u003cul data-start=\"6902\" data-end=\"7520\"\u003e\r\n\u003cli data-start=\"6902\" data-end=\"7025\"\u003e\u003cstrong data-start=\"6904\" data-end=\"7023\"\u003e\u003ca target=\"_new\" rel=\"noopener\" data-start=\"6906\" data-end=\"7021\"\u003eFDA Entresto Prescribing Information\u003c\/a\u003e\u003c\/strong\u003e\u003c\/li\u003e\r\n\u003cli data-start=\"7026\" data-end=\"7249\"\u003e\n\u003cstrong data-start=\"7028\" data-end=\"7121\"\u003e\u003ca target=\"_new\" rel=\"noopener\" data-start=\"7030\" data-end=\"7119\"\u003eREDUCE‑IT Trial – NEJM Publication\u003c\/a\u003e\u003c\/strong\u003e (Note: The REDUCE‑IT trial specifically evaluated Icosapent Ethyl; for Sacubitril\/Valsartan, refer to the PARADIGM‑HF trial.)\u003c\/li\u003e\r\n\u003cli data-start=\"7250\" data-end=\"7432\"\u003e\n\u003cstrong data-start=\"7252\" data-end=\"7335\"\u003e\u003ca target=\"_new\" rel=\"noopener\" data-start=\"7254\" data-end=\"7333\"\u003ePARADIGM‑HF Trial – NEJM\u003c\/a\u003e\u003c\/strong\u003e which demonstrated the benefits of Sacubitril\/Valsartan over enalapril in patients with HFrEF.\u003c\/li\u003e\r\n\u003cli data-start=\"7433\" data-end=\"7520\"\u003e\n\u003cstrong data-start=\"7435\" data-end=\"7481\"\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/\" target=\"_new\" rel=\"noopener\" data-start=\"7437\" data-end=\"7479\"\u003ePubMed\u003c\/a\u003e\u003c\/strong\u003e for additional peer‑reviewed research.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"7522\" data-end=\"7643\"\u003e\u003cem data-start=\"7522\" data-end=\"7643\"\u003eReference: McMurray, J. J. V. et al. “Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure.” NEJM, 2014.\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"7645\" data-end=\"7648\"\u003e\r\n\u003ch3 data-start=\"7650\" data-end=\"7670\"\u003eFinal Thoughts\u003c\/h3\u003e\r\n\u003cp data-start=\"7671\" data-end=\"8343\"\u003e\u003cstrong data-start=\"7671\" data-end=\"7706\"\u003eSacubitril\/Valsartan (Entresto)\u003c\/strong\u003e is a groundbreaking ARNI that offers significant benefits for patients with chronic HFrEF. By combining the neprilysin inhibitor sacubitril with the ARB valsartan, it effectively reduces triglyceride levels, lowers blood pressure, and decreases the risk of major cardiovascular events. Supported by robust clinical evidence from the PARADIGM‑HF trial, Sacubitril\/Valsartan represents a major advancement in heart failure management. However, due to its potential risks—including angioedema, hypotension, and hyperkalemia—it must be used under strict medical supervision with regular monitoring for adverse effects and drug interactions.\u003c\/p\u003e\r\n\u003cp data-start=\"8345\" data-end=\"8569\"\u003e\u003cem data-start=\"8345\" data-end=\"8569\"\u003eDisclaimer: This information is provided for educational purposes only and should not replace professional medical advice. Always consult with your healthcare provider before initiating or modifying any medication regimen.\u003c\/em\u003e\u003c\/p\u003e","brand":"EZ Chemist","offers":[{"title":"50mg","offer_id":51736357503259,"sku":"Entresto-50mg","price":34.62,"currency_code":"USD","in_stock":true},{"title":"100mg","offer_id":51736357536027,"sku":"Entresto-100mg","price":51.97,"currency_code":"USD","in_stock":true},{"title":"200mg","offer_id":51736357568795,"sku":"Entresto-200mg","price":69.3,"currency_code":"USD","in_stock":true}],"url":"https:\/\/ezchemist.com\/products\/entresto","provider":"EZ Chemist","version":"1.0","type":"link"}